The global biosurgery market is projected to reach USD 15.58 billion by 2023 from USD 11.36 billion in 2018, at a CAGR of 6.5%. The global biosurgery market is fragmented with various regional and multinational market players. In 2017, Baxter (US), Johnson & Johnson (J&J) (US), and Medtronic (Ireland) dominated the biosurgery market. These players together accounted for 55%–60% of the market share.
In 2017, Baxter dominated the global biosurgery market. The company has a strong presence across North America, Europe, the Middle East, Africa, and Asia Pacific. Some of the major end users of the company include hospitals, nursing homes, kidney dialysis centers, clinical and medical research laboratories, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. The company’s strong manufacturing and distribution network across the globe has enabled it to establish a strong foothold in the biosurgery market. Collaborations and product launches are some of the major strategies adopted by the company in order to grow in this market.
To know about the assumptions considered for the study download the pdf brochure
Johnson & Johnson (J&J) held the second position in the global biosurgery market in 2017. The company offers its products through two of its subsidiaries, namely, Ethicon, Inc. (US) and DePuy Synthes (US). The major end users of the company’s products include physicians, nurses, clinics, and hospitals. Over the years, the company has strongly established itself in North America, Europe, the Middle East and Africa, and Asia Pacific. The company has a wide product portfolio, which enables it to strengthen its presence in the biosurgery market. Like J&J, Ethicon also has a diverse product portfolio, and more than 600 general surgical products of the company are listed in the US FDA. Most of these products have patent exclusivity in the US beyond 2020, which will help the company sustain its market position. Ethicon harnesses J&J’s worldwide infrastructure to sell its products. Ethicon also gets benefited through synergies with its parent company in R&D, technological know-how, business strategies, and project implementation experience.
Medtronic (Ireland) held the third position in the global biosurgery market in 2017. The company is a multinational medical technology company that manufactures and markets products for alleviating pain and restoring health. The company’s products are used by hospitals, clinics, third-party healthcare providers, distributors, and other institutions (including governmental healthcare programs and group purchasing organizations). Medtronic has a well-diversified business and strong geographic presence in the market. The company has a strong presence in the US market and is expanding its reach in emerging markets. For instance, in 2016, the company opened its regional headquarters in Singapore to improve its market presence in the Asia Pacific market. Medtronic offers soft-tissue attachment products through its subsidiary-Covidien. Covidien offers synthetic monofilament meshes, composite meshes, and biologic meshes. The company also offers tack applicators for mesh fixation. Medtronic offers its mesh fixation tacks under the brand name-ProTack.
Some of the other players operating in this market include Sanofi Group (France), B. Braun Melsungen AG (Germany), MAQUET Holding B.V. & Co. KG. (Germany), CryoLife, Inc. (US), Stryker Corporation (US), and Hemostasis, LLC. (US), Integra Lifesciences Holdings Corporation (US), Cohera Medical Inc. (US), Pfizer Inc. (US), CSL Limited (Australia).
Related Reports:
Biosurgery Market by Product (Fibrin & Collagen Sealant, Hemostats, Adhesion Barriers, Biological Meshs, Soft Tissue Attachments, Stapler, Bone Graft Substitues) Application (Orthopedic, Gynecology, Cardiovascular, Reconstructive) - Forecast to 2021
